Hawaii Biotech announced the successful completion of a Phase I clinical trial for its West Nile Virus vaccine. The recombinant sub-unit vaccine was found to be safe among healthy volunteers who had not been exposed to the virus. The company says it is preparing to proceed with additional safety studies in adults, and later plans to expand the studies to include elderly, juvenile and immunocompromised populations.
"We are extremely pleased with the safety results of our West Nile Virus vaccine Phase 1 study and are encouraged by the presence of neutralizing antibodies in all individuals receiving the formulated vaccine," noted president and CEO Dr. Elliot Parks. "Additionally, these results demonstrate the robustness of our protein production platform for the development of additional sub-unit vaccines in our product pipeline."
- check out the Hawaii Biotech release for more